^
    Back
    Association details:
    Biomarker:POLE mutation
    Cancer:Colorectal Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2021
    Title:

    PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.

    Published date:
    05/19/2021
    Excerpt:
    Four metastatic CRC patients with LOP POLE mutation were treated with immune therapy (nivolumab, or ipilimumab/nivolumab) in 2nd or 3rd line, all four achieved objective response and remain on therapy (mean time on treatment 15 mo).
    DOI:
    10.1200/JCO.2021.39.15_suppl.3548